Similar articles

• Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.

  Vogelzang NJ, Bonomi PD, Rossof AH, Wolter J. Vogelzang NJ, et al. Cancer Treat Rep. 1978 Oct;62(10):1595-7. Cancer Treat Rep. 1978. PMID: 709563 No abstract available.
• Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP.

  Ruckdeschel JC, Mehta CR, Salazar OM, Creech RH, Sponzo RW. Ruckdeschel JC, et al. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):959-63. Cancer Treat Rep. 1981. PMID: 6794909 Clinical Trial.
• Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.

  Vogelzang NJ, Trowbridge RC, Frenning DH, Theologides A, Kennedy BJ, Kelly DR, Ewing SL, Vosika GJ. Vogelzang NJ, et al. Cancer Treat Rep. 1980 Aug-Sep;64(8-9):997-1000. Cancer Treat Rep. 1980. PMID: 6256076
• Management of small cell cancer: intensive chemotherapy.

  Smyth JF, Gregor A. Smyth JF, et al. Recent Results Cancer Res. 1984;92:58-64. doi: 10.1007/978-3-642-82218-6_5. Recent Results Cancer Res. 1984. PMID: 6330811 Review. No abstract available.
• [Polychemotherapy and radiotherapy for small cell cancer of the lung].

  Linchenko IF, Danil'ian VM. Linchenko IF, et al. Vopr Onkol. 1983;29(9):106-14. Vopr Onkol. 1983. PMID: 6314659 Review. Russian. No abstract available.